Regression of Papillary Thyroid Cancer during Nivolumab for Renal Cell Cancer

Immune checkpoint inhibitors have been recently approved for cancer treatment. Nivolumab is a monoclonal antibody specific for programmed cell death-1 (PD-1) that modulates T-cell response. It was initially used for the treatment of malignant melanoma and then approved in other cancers, such as non-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur Thyroid J
Autors principals: Palermo, Andrea, Napolitano, Andrea, Maggi, Daria, Naciu, Anda Mihaela, Tabacco, Gaia, Manfrini, Silvia, Crescenzi, Anna, Taffon, Chiara, Pantano, Francesco, Vincenzi, Bruno, Tonini, Guiseppe, Santini, Daniele
Format: Artigo
Idioma:Inglês
Publicat: S. Karger AG 2020
Matèries:
Clinical Thyroidology / Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7265713/
https://ncbi.nlm.nih.gov/pubmed/32523892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000506107
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars